• Focused on developing remedies from cannabis oil
• Research programs in conjunction with Universities of Waterloo & Western Ontario
• Strategy to capture market share of non-smoke MMJ nutraceuticals

To acquire the benefits of cannabis, there are many pathways, with some being distinctly safer than others. There are tinctures and topicals; there is dabbing; and there is vaping. There are drinks and digestibles and, of course, there is smoking. Over the last few decades, what some wits refer to as ‘puffing the magic dragon’ has emerged as the top delivery method for users of cannabis, but smoking harms nearly every organ of the body and causes many diseases, according to the Centers for Disease Control (CDC) (http://dtn.fm/eZ5Tg). Given such adverse aftereffects, interest in safer delivery options, like those made possible by technology from Algae Dynamics Corp. (OTC: ADYNF), has grown. Algae Dynamics is an innovative biotech currently engaged in the development of nutraceuticals and pharmaceuticals utilizing hemp, cannabis and algae oils. The company plans to be a global leader in the formulation and development of health products from cannabis derivatives, algae oils and other botanical oils.

The days when inhaling and exhaling tobacco fumes was regarded as chic or sophisticated are long gone. Now that the danger from cigarettes has been laid bare, the glamour long associated with them has evaporated much as their smoke does. Smoking is responsible for about 480,000 deaths each year in the United States; that is nearly one in five deaths, a figure that exceeds the combined fatalities due to HIV, illegal drug use, alcohol, motor vehicle accidents and gun-related incidents. Notably, ‘more than 10 times as many U.S. citizens have died prematurely from cigarette smoking than have died in all the wars fought by the United States’, according to the U.S. Surgeon General (http://dtn.fm/I0LlZ). These compelling statistics, together with government and private initiatives, have raised awareness of the threats posed by smoking, which extend not only to the use of tobacco but also to the newly emerging therapeutic treatments based on cannabis.

In response to the imperative for safer delivery of cannabinoids, Algae Dynamics has been working with two of Canada’s leading research universities – the University of Western Ontario and the University of Waterloo. This collaborative research is focused on the use of extracts from cannabis oil to treat some mental health issues and various forms of cancer. The program at the University of Western Ontario is studying the effects of cannabis oil on depression, post-traumatic stress disorder (PTSD), anxiety and schizophrenia, while research at the University of Waterloo is examining ways of treating colorectal, pancreas, breast and prostate cancers.

To support these research efforts, Algae Dynamics announced in August 2017 that it would be collaborating with Bonify, a Licensed Producer (LP), under the Access to Cannabis for Medical Purposes Regulations (ACMPR) in Canada, to engage in the extraction of cannabis oil, according to MarketWatch (http://dtn.fm/7yhMW). The joint initiative entails the purchase and installation of cannabis oil extraction equipment by ADYNF at Bonify’s facility in Winnipeg, Canada. This deal will secure cannabis material for extraction and will generate revenue. As well, the cannabis oil thus produced will be supplied to the University of Waterloo and University of Western Ontario to support the Sponsored Research Agreements that ADYNF has in place with the two universities.

The market for cannabis oil is still in its embryonic stage, but it is likely to grow quickly, spurred by recent trends. A 2016 Mackie Research Capital report, extrapolating data from Colorado, one of the first U.S. states to legalize marijuana, estimates that 45 percent of dried marijuana users would eventually convert to marijuana extracts and/or oils. New Cannabis Ventures even billed cannabis extracts as ‘The Next Canadian Oil Boom’ (http://dtn.fm/I4ZRn) after a court ruling allowing LPs to produce cannabis extracts. The Canadian cannabis oil extraction market is projected to grow to C$1.7 billion by 2020. With legalization for recreational use set for July 2018, safer delivery routes for cannabis therapeutics like those engineered by Algae Dynamics are sorely needed to help customers and patients avoid the hazards of smoking.

For more information, visit the company’s website at www.AlgaeDynamics.com

Let us hear your thoughts: Algae Dynamics Corp. Message Board

• Rapidly expanding network of analytical cannabis testing laboratories now serving five states
• Accurate, reliable lab results based on scientific principles using state-of-the-art facilities
• Analytical services include testing cannabis flowers, extracts and infused products

EVIO, Inc. (OTCQB: EVIO), via the EVIO Labs division, is the nation’s leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation’s cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

• Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
• Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
• Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
• Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
• Detection of harmful residual solvents left behind in the cannabis extract production process.
• Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
• Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation’s leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today’s fastest growing industry.

For more information, visit the company’s website at www.EVIOLabs.com

Let us hear your thoughts: EVIO, Inc. Message Board

• Patented technology enhances how topical and transdermal drugs and skin care products are delivered
• Polymer delivery vehicle can be tailored to almost any type of molecule including the medicinal components of hemp and marijuana
• 14 patents granted in the U.S. and internationally
• $65 billion market in dermatology, pharmaceutical and other healthcare industries offers strong growth opportunity

Skinvisible, Inc. (OTCQB: SKVI), through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible’s formulations to sell their own patented product and combat generic competitors.

A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of “gold standard” dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.

Invisicare® is a high performance topical and transdermal delivery system which enhances the delivery of drugs and other ingredients to and through the skin. The key to Skinvisible’s patented technology and trademarked Invisicare® family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Invisicare® can be a key component of life cycle management, extending the life with a new patent-protected product, dramatically expanding the company’s revenue stream.

Independent studies of Invisicare ® have shown the following benefits:

• Active ingredients stay on the skin for up to four hours or more and resist wash off and rub off.
• Delivery method results in improved efficacy, reduced skin irritation and lower required dosage.
• Unique formulations are non-drying and provide the ability to control the release of active ingredients.
• Products form a protective barrier, which means normal skin respiration and perspiration occur and the product wears off as part of the skin’s natural exfoliation process.

Terry Howlett, President, founder and CEO of Skinvisible Inc., said the Company has more than 15 years of scientific research and product development experience. All development is conducted using stringent pharmaceutical standards. The Company has licensed a number of its formulations including a prescription hemorrhoid cream in the USA, its anti-aging Kintari® line of products and DermSafe®, its non-alcohol hand sanitizer to a licensee in China. Producing licensed products for the booming cannabis industry is also an important element of the company’s business strategy.

Skinvisible’s foray into the rapidly expanding market for medicinal and recreational cannabis products is already underway with the development of the company’s first hemp-derived CBD (cannabidiol) products. Skinvisible has negotiated an exclusive licensing deal in Canada with Canopy Growth Corporation, one of the world’s leading cannabis companies. As part of the company’s overall growth strategy, Skinvisible is also negotiating with a Licensed Producer in Las Vegas where Skinvisible scientists will develop THC (tetrahydrocannabinol) products for the legal recreational and medical marijuana market for the USA. Notably, Skinvisible is actively pursuing potential licensees through-out the world where medical cannabis is legal. These licensees will have the exclusive right to manufacture and distribute Skinvisible’s cannabis products within their territory.

“We are excited about the results we are already seeing just with our hemp-derived CBD products,” Howlett says. “Our science shows that our CBD products release almost four times that of market leaders and our transdermal product had an 81% penetration rate at 6 hours. These results are significant and provide the difference between ordinary cannabis products and ones enhanced by Invisicare.”

The Company’s business model includes out-licensing its formulations for a development fee, license fee and on-going royalties in addition to selling its Invisicare polymers to its licensees.

For more information, visit the company’s website at www.Skinvisible.com

Let us hear your thoughts: Skinvisible, Inc. Message Board

• Companies collaborating on development of patent-pending sustained release oral cannabinoid formulation
• Formulation doubles or triples time period in which cannabinoid doses maintain their therapeutic effects
• Formulation enables better regulation of dosing schedules and improvement of patient compliance

Emblem Corp. (TSX.V: EMC) (OTC: EMMBF), a company licensed to cultivate and sell medical marijuana in Canada under the Access to Cannabis for Medical Purposes Regulations, has entered into a collaboration and licensing agreement with Canntab Therapeutics Limited to collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of Canntab’s patent-pending oral sustained release formulation for cannabinoids.

Through this agreement, Emblem gains the exclusive right to Canntab’s patents and expertise in Canada to develop, commercialize, use, sell and offer the sustained release product, which will be sold under the Emblem brand. The license does not grant Emblem the right to import or export the product.

Emblem or Canntab will manufacture the product, once Canntab obtains the necessary licensing for such manufacture.

As stipulated in the agreement, Emblem will make payments to Canntab once certain milestones have been achieved relative to stability studies, bioavailability studies and regulatory approval of the product. Further, the agreement states that Emblem will make royalty payments to Canntab based on gross product sales.

In addition, the two companies plan to collaborate on the preclinical formulation, clinical development, regulatory approval and commercialization of various additional pharmaceutical formulations containing cannabinoids.

Considerable evidence exists showing the efficacy of cannabinoids in treating a variety of conditions, such as chronic pain, anxiety, nausea, sleep disorders and spasticity in multiple sclerosis patients. The majority of conventional immediate release dosage forms, like capsules and tablets, release an active drug component immediately following oral administration. In formulating conventional drug products, there is no deliberate effort to alter the drug release rate.

In sustained release dosage forms, active pharmaceutical ingredients are released at a predetermined rate, so constant drug concentration can be maintained over a specific time period. This results in a single dose having greater duration of action and, frequently, a reduction of side effects. The end goal is typically to improve the therapeutic outcome and/or enhance patient compliance.

In the case of cannabinoids, the therapeutic effects of immediate release dosage forms often diminish within four to six hours, which necessitates re-administering the dosage and risks a reduction in patient compliance. Canntab’s sustained release product, however, has been designed to release cannabinoid content over at least a 12-hour period.

Considerable evidence shows the effectiveness of cannabis in treating conditions like neuropathic pain, which has been estimated to affect more than two million Canadians. The pharmaceutical market for addressing these patients’ needs was approximately $500 million in 2016. Sustained release formulations of pharmaceutical products to treat chronic conditions—conditions necessitating 24-hour relief for patients—is of especial value.

For pharmaceutical ingredients that are typically short-acting, like cannabinoids, sustained release formulations enable dosage schedules that are more convenient, offer longer action duration and are better accepted by health care professionals and patients. The patent-pending extended release formulation being collaboratively developed by Emblem and Canntab will enable medical professionals, for the first time, to establish proper dosages for patients and will, for the patients, make it easier to take medical cannabis.

Emblem believes the development of advanced dosage forms, and the pharmacokinetic and clinical research associated with this development, will effectively advance cannabinoid therapy. The company also anticipates that introducing sustained release cannabinoid formulations that are easily titratable will significantly increase the market for cannabinoid-based medications—especially for the treatment of conditions like chronic neuropathic pain.

For more information, visit the company’s website at www.EmblemCannabis.com

• Strategic approach to cannabis and hemp industry through networking architecture
• Legal marijuana markets estimated to reach $22.6 billion by 2021
• Branded “hempSMART Brain™” CBD product is first to be offered by direct market
• Wellness industry is now $1.9 trillion per year with huge growth potential

The founders of Marijuana Company of America, Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a US stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing expotentially and consequently the founders of MCOA have contructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can also be used to produce products that are carbon neutral or even carbon negative, like the longest, strongest natural fiber on earth, building materials that are mold, pest and fire proof, super foods and so much more for additional business opportunities. No part of the plant is left unused and the Company’s overall stategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented exponential growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal and cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

Let us hear your thoughts: Marijuana Company of America, Inc. Message Board

• Acquisition provides GRCK with an entry into the CBD market
• Eqova is fully-focused on providing hemp oil health products to partners in the medical practitioner market and plans to dominate that niche
• The CBD market is seen growing 700% to $2.1 billion by 2020, according to The Hemp Business Journal

Grey Cloak Tech, Inc.’s (OTC: GRCK) signing of a binding letter of intent to purchase CBD company Eqova Life Sciences is expected to enable it to enter the medical practitioner market (http://dtn.fm/0itCb). Eqova is a company that’s focused exclusively on offering a full spectrum line of clinical-grade hemp oil products via partnerships with licensed practitioners to use with their patients. The transaction is scheduled to close by October 10, 2017, according to EmergingGrowth.com (http://dtn.fm/Wpp1u).

GRCK is a Las Vegas, Nevada-based company that develops advanced software that is designed to overcome the most costly digital threats. It offers unique systems which are aimed at eliminating online fraud. Its proprietary digital advertising fraud detection software is FraudLytic™, which is a cloud-based platform that monitors internet traffic in real time. Fred Covely, GRCK’s CEO, said on Big Biz Radio that GRCK is focused on detecting digital ad fraud, including the number of ad ‘clicks’ claimed by online advertisers (http://dtn.fm/1ySW0).

Eqova is a Denver, Colorado-based firm that focuses entirely on providing CBD to the medical practitioner market, which GRCK believes is underserved. In addition to its own branded product line of hemp oil health products, it also offers private labels to qualified partners.

The CBD market is seen growing by 700% to $2.1 billion by 2020, according to The Hemp Business Journal (http://dtn.fm/1TTub).

For more information, visit the company’s website at www.GreyCloakTech.com

• Diversified portfolio for sustainable growth offers multiple revenue options
• Entry into legalized cannabis market continues with acquisition of multiple cannabis companies
• Ancillary cannabis-related businesses poised to reap healthy portion of multi-billion-dollar industry

SinglePoint, Inc. (OTC: SING) has evolved from a full-service provider of mobile technology to a publicly traded holding company focused on diversifying into horizontal markets that offer multiple revenue streams for investors. Key to this approach is SinglePoint’s strategic expansion into the burgeoning legal marijuana industry, which includes the acquisition of several important cannabis-related brands.

Projected growth estimates for the legal marijuana industry continue to brighten the mood of investors, with ArcView Market Research noting the North American cannabis market alone is expected to reach $22 billion by 2021 (http://dtn.fm/JDHs7). Globally, the market is estimated to reach over $55 billion by 2025. SinglePoint is positioning itself to take full advantage of a variety of business opportunities this booming market presents for those willing to seek revenue in supportive or horizontal ventures.

SinglePoint’s most recent announcement that it intends to acquire 51 percent of a Colorado-based company approaching $1 million in annual revenue drives home the success of its revenue-by-acquisition model (http://dtn.fm/3AGwP).

In March 2017, SinglePoint’s investment in Convectium, a California-based provider of equipment, packaging and branding solutions for the cannabis industry, propelled the company’s business reach. Two months later, SinglePoint acquired Discount Indoor Garden Supply (DIGS), which supplies soil, supplies hydroponics and consulting services to legal cannabis growers in California. Each of these successful acquisitions is factored into SinglePoint’s strategic plan to create additional revenue streams while identifying undervalued companies to consider as potential targets.

Meanwhile, SinglePoint’s SingleSeed subsidiary (www.SingleSeed.com) continues to offer various services to marijuana enterprises, including payment processing and text messaging marketing solutions. SingleSeed Payments exists to educate and inform customers and shopkeepers of the changing key issues in the retail and medicinal cannabis market while helping to legitimize the industry. By staying flexible and responsive to these changes, SingleSeed provides its customers with a unique experience backed by an ethical and responsible approach to challenges facing the cannabis industry.

SinglePoint’s proactive approach to seeking out new business ventures has increased the company’s revenue 378-fold in Q2, as compared with the first quarter of 2017. This ability to specialize through the acquisition of small to mid-sized companies, with an emphasis on new technologies, provides investors with the opportunity to reap rewards across a wide range of assets.

For more information, visit the company’s website at www.SinglePoint.com

Let us hear your thoughts: SinglePoint, Inc. Message Board

• Strategic holdings in telemedicine, remote diagnostics, healthcare services, medical device development and patient services
• Feds have endorsed telehealth services, signaling growth opportunities for Medical Innovation Holdings
• In process of acquiring nutraceutical company Renaissance Health Publishing LLC, bolstering bottom line and product offerings

Medical Innovation Holdings, Inc. (OTC: MIHI), a Colorado-based publicly traded company, owns and operates strategically aligned healthcare service and product companies focused on the delivery of patient care, management services for physician offices, lab services, and pharma; and non-pharma medicines and alternatives to patients and consumers. Healthcare services are delivered and managed through the company’s MSO, 3Point Care. 3Point Care uses virtual telemedicine with a unique customized software and hardware platform as a way of bringing quality medical care to rural and medically underserved areas (MUAs) of the country.

3Point Care provides personalized high-tech, high-touch telemedicine encounters that link virtual health specialty doctors with traditional primary physicians and their patients. This approach helps reduce the cost of care while enhancing the quality of care. The company’s telemedicine approach is vastly different from other providers who rely on a monthly subscription to opt in the network and then require an encounter fee by the patient each and every time an on-demand physician is utilized. This approach breaks the continuum of care, relies on symptom-based diagnosis, does not except insurance, and there is no certainty you are dealing with a licensed practitioner. In summation they are not a medical practice but a contract service to deliver virtual care. Because 3Point Care deploys doctors through an actual medical practice, there is no subscription fee. The company works with anyone and everyone that has insurance including Medicare and Medicaid. It works hand and hand with the patient’s primary care physician so the continuum of care is always maintained. Part of the integrated software application enables the processing of insurance claims whereby doctors are paid for their services. This allows deductibles to be captured, allowing the patients to take advantage of medical tax deductions.

TeleLifeMd, a multi-disciplinary specialty healthcare practice with strong experience in telemedicine, is the primary deliverer of patient medical care. 3Point care has a unique and exclusive relationship with TeleLifeMD, acting as its management services organization by providing all levels of service that include scheduling, providing telemedicine hardware and software products and support, processing claims, paying all invoices and payroll incurred by TeleLifeMD, as well as any other service required to operate the practice.

BKare Diagnostics, another wholly owned subsidiary of MIHI, is tasked with delivering medical and health-related services such as laboratory testing, diagnostics, and alternative medicines primarily proven nutraceuticals. Its goal is to eventually infuse these products with 100% CBD/Hemp oil and THC-based oils to create new product categories as the law catches up with the cannabis marketplace. The opportunity to offer workable solutions that solve real health problems outside typical big pharma is very exciting for the company. It sees significant revenue opportunities in this space.

MIHI firmly believes the best way to provide access to high-quality medical care is through support and delivery of evidence-based virtual medicine, commonly known as telemedicine. With 80 million people living in rural, medically underserved areas of the nation, the company is poised to fill a glaring void in the healthcare industry by applying cutting-edge technology and time-tested business practices to deliver real-time care. Among the 16 areas of medical specialties available are cardiology, infertility, gastroenterology, pediatrics and obstetrics.

The company serves a number of constituents and stakeholders interested in reducing the cost of health care while simultaneously increasing the quality of care, improving access to health services for millions of people, and bringing value to company shareholders. Its unique platform incorporates every aspect of a telemedicine visit into a single, comprehensive package.

For more information, visit the company’s website at www.MedicalInnovationHoldings.com

Let us hear your thoughts: Medical Innovation Holdings, Inc. Message Board

• UnionPay module in Moxian+ User and Moxian+ Business apps gives access for potential joint venture partners to China’s largest payment processor
• Hao Qing Hu named as new company president and CEO in addition to Moxian director
• Seven directors elected to Moxian’s board at annual meeting, including Shewn International Group CEO Ms. Liu Shu Juan

Moxian, Inc. (NASDAQ: MOXC) has a key ingredient to attract joint venture partners in its growth strategy in China: the UnionPay module in its new User and Business apps. UnionPay is the largest payment processor in China and owns 25% of the global market for credit cards, third only to Visa and MasterCard (http://dtn.fm/dKz6h). It also has a presence in more than 160 countries worldwide, including the U.S.

Moxian is an integrated social media platform operator, striving to convert its unpaid Moxian+ Business and Moxian+ User platforms to paid within the online-to-offline (O2O) market in China. It connects users to merchant clients through games, rewards and social events. It offers Mo-Coin and Mo-Point reward systems.

MOXC’s special relationship to UnionPay gives businesses and vendors in China access to the largest payment processor in the country. MOXC has a new growth strategy employing partners to help it expand into more Chinese cities quicker and with lower costs. It signed an agreement in principal for its first joint venture partner, Shewn International Group of Shanghai, a successful marketer of fine wines in China. UnionPay makes MOXC a desirable partner for Shewn.

Crystal Equity Research LLC projects that Moxian will generate sales of $2.3 million in FY2018, in part from the new revenue stream of receiving a fee of 1% of all Shewn payments processed on Moxian’s UnionPay app (http://dtn.fm/76hJy). Crystal Equity Research also noted that Moxian has reduced its spending to $1.3 million for the quarter ended June 2017, down from the $5.4 million it spent in the prior quarter due to reduced selling, general and administrative (SG&A) expenses. Crystal Equity Research said it anticipates raising its projections for Moxian’s revenues after the Shewn joint venture is executed.

At the company’s annual meeting, Hao Qing Hu was named the company’s president and CEO and also elected as a director of the company. He has been a director of Moxian since January 2016 and, since September 2015, has been the general manager of subsidiary Moxian Beijing, maintaining responsibility for all operations.

Additionally, Ms. Liu Shu Juan was elected director. She is CEO of Shewn International Group and financial controller of Shanghai Shewn Co., Ltd., the company’s primary operator in China.

For more information, visit the company’s website at www.Moxian.com

• CBD market estimated to grow by 700% by 2020
• POTN has scientific focus on quality and therapeutic consistency
• POTN multiple product lines and global distribution
• Positioned for outsized share of the growth

It’s no wonder that medicinal marijuana, cannabis and hemp (cannabidiol) has become a veritable gold rush given the 700% market upsurge projected over the next three years (http://dtn.fm/Vx98o). Millions of people currently use cannabis, including CBD products, for medical therapies to treat pain, epilepsy, depression and multiple other maladies according to many abstracts and studies available from the U.S. National Library of Medicine National Institutes of Health. From these reports, there appears to be an abundance of scientific evidence proving the medical efficacy of cannabidiol (CBD) and investors are flooding the space seeking a share of this colossal 700% growth.

With such enormous upside in this space there are many pretenders to the throne and investors should be careful to look for companies that already have product lines, plus revenues and earnings instead of just hyped up pipe dreams. PotNetwork Holding Inc. (OTC: POTN) meets these criteria with an established product line and a successful business model. The company was recently mentioned in a NetworkNewsWire article, “Cannabis Companies Cater to an Increasingly Large and Diverse Industry” “(http://dtn.fm/3xK0l).

PotNetwork Holding is a holding company that owns subsidiaries that produce and distribute cannabidiol both in the U.S. and internationally. A primary operating entity of PotNetwork, Diamond CBD, Inc., produces and controls 15 different CBD brands that have gained international acceptance for both quality and consistency. With a staff of doctors, chemists and scientists, Diamond CBD is dedicated to developing and producing only the highest quality CBD oil across multiple products for a myriad of therapeutic and beneficial uses. Scientific research and depth of knowledge of natural hemp molecules and their particular properties determines the course of product development. All of the company’s products are made with federally legal cannabidiol (CBD) and are available in a variety of flavors and sizes for consumer appeal. The company insists on 100% natural lab-tested CBD ingredients with the process meticulously monitored from the source farm through every stage of production and final delivery to retail outlets.

Company efforts and attention to quality are paying off. PotNetwork recently announced that its Diamond CBD, Inc. subsidiary delivered a 30% month-over-month increase in revenues. Maria Gomez, Regional Vice President of Sales for Diamond CBD, Inc., stated in the news release, “We are consistently setting new sales records month after month and are excited to be able to report this type of continuing growth. We have taken our marketing efforts seriously. A commitment that is surely being revealed in the ongoing sales numbers.” These revenue results place PotNetwork on track to easily exceed 2017 projections.

With a scientific focus on quality and therapeutic consistency, 15 different brands in multiple flavors and sizes, with both domestic and international sales rapidly ramping up and in the midst of a 700% upsurge market, it looks like PotNetwork is well positioned to snag more than its fair share of this massive growth.

For more information, visit the company’s website at www.PotNetworkHolding.com

Let us hear your thoughts: PotNetwork Holding, Inc. Message Board